Sitazit-M (Sitagliptin Hydrochloride + Metformin)

Sitagliptin + metformin is a widely used fixed‑dose combination therapy for type 2 diabetes, designed to improve glycemic control through two synergistic mechanisms. Sitagliptin, a DPP‑4 inhibitor, enhances the body’s natural incretin system to increase insulin secretion and reduce glucagon levels when blood glucose is elevated. Metformin, the first‑line biguanide agent, decreases hepatic glucose output and improves peripheral insulin sensitivity. Together, they provide effective HbA1c reduction, target both fasting and post‑prandial glucose, and maintain a low risk of hypoglycemia. This combination is weight‑neutral, convenient for long‑term therapy, and commonly recommended when metformin alone is insufficient or when patients require a simplified regimen. It is available in immediate‑release and extended‑release formulations, making it adaptable to patient tolerance and dosing preferences.